Crohn's Disease Clinical Trials

A listing of Crohn's Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 321 clinical trials
A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn's Disease (CULTIVATE)

active Crohn's disease (CD) who are refractory or intolerant to at least 1 of the current therapies for CD (ie, corticosteroids, immunosuppressants, or biologics). The overall duration of this study is

immunosuppressive agents
certolizumab pegol
tumor necrosis factor alpha
budesonide
infliximab
  • 207 views
  • 20 Sep, 2022
  • 323 locations
A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy

Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, children and teenagers with moderate to severe Crohn's disease will be treated with

colitis
crohn's disease
infliximab
immunomodulators
mercaptopurine
  • 0 views
  • 14 Sep, 2022
  • 41 locations
A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of BI 706321 Orally Administered for 12 Weeks in Patients With Crohn's Disease (CD) Receiving Ustekinumab Induction Treatment

This study is open to adults, aged 18-75 years, with moderate to severe Crohn's disease. The purpose of this study is to find out whether BI 706321 combined with ustekinumab helps people

azathioprine
ulceration
prednisone
endoscopy
budesonide
  • 1 views
  • 17 Sep, 2022
  • 34 locations
  • 0 views
  • 20 Sep, 2022
  • 3 locations
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Crohn's Disease (CD): AIM-CD (AIM-CD)

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. CD may cause tiredness, loose stools with or without bleeding, abdominal pain, weight

natalizumab
adalimumab
certolizumab pegol
infliximab
crohn's disease
  • 19 views
  • 23 Sep, 2022
  • 120 locations
  • 0 views
  • 21 Sep, 2022
  • 21 locations
Anastomotic Leakage and Value Of Indocyanine Green in Decreasing Leakage Rates

Anastomotic leakage (AL) is one of the major complications after gastrointestinal surgery. Compromised tissue perfusion at the anastomosis site increases the risk of AL. Indocyanine green (ICG) combined with fluorescent near infrared imaging has proven to be a feasible and reproducible application for real-time intraoperative quantification of the tissue perfusion …

  • 0 views
  • 03 Feb, 2021
  • 1 location
A Phase 3, Multicenter, Open-label, Basket, Long-term Extension Study of Ustekinumab in Pediatric Clinical Study Participants (2 to <18 Years of Age) (UNITED)

The purpose of this study is to collect long-term safety data of subcutaneous (SC) ustekinumab

remission
ustekinumab
  • 0 views
  • 19 Aug, 2022
  • 12 locations
ENhanced Recovery in CHildren Undergoing Surgery (ENRICH-US)

The institution of perioperative Enhanced Recovery Protocols (ERPs) has been found to decrease hospital length of stay, in-hospital costs, and complications among adult surgical populations but data in pediatric populations are lacking. The Assessing Effectiveness and Implementation of a Perioperative Enhanced Recovery Protocol for Children Undergoing Gastrointestinal Surgery, which has …

ulceration
enteropathy
colitis
Accepts healthy volunteers
inflammatory bowel disease
  • 0 views
  • 12 May, 2022
  • 1 location
A 52-Week, Multicenter, Randomized, Double-blind, Placebo and Active-Controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease (INTREPID Lead-In) (INTREPID)

This study seeks to evaluate the safety and efficacy of brazikumab versus placebo (Stage I) and versus an active comparator (Stage 2) in participants with moderately to severely active CD and will include assessments of clinical response as demonstrated by improvement of symptoms and colonic mucosal appearance as observed on …

azathioprine
prednisone
conventional treatment
endoscopy
budesonide
  • 550 views
  • 14 Sep, 2022
  • 77 locations